Influenza h1n1 tretamnet protocol in mumbai
Reading File
Finding Sources
Searching the Web
H1N1 swine flu treatment protocol Mumbai India 2025 2026 guidelines
Searching PubMed
influenza H1N1 treatment protocol oseltamivir India
Reading File
Searching the Web
India Ministry of Health H1N1 influenza treatment protocol case classification oseltamivir 2025
Finding Sources
Reading File
Reading Web Page
https://ncdc.mohfw.gov.in/uploads/pdf/72513234671561442053-1…
Here is the complete H1N1 (Swine Flu) treatment protocol as applicable in Mumbai / Maharashtra, based on the National NCDC/MoHFW guidelines (which Mumbai's BMC and Maharashtra health department follow), textbook references, and the latest national antimicrobial treatment guidelines (November 2025):
Influenza H1N1 Treatment Protocol - Mumbai / Maharashtra
Background
Mumbai follows the Ministry of Health & Family Welfare (MoHFW) / National Centre for Disease Control (NCDC) guidelines for H1N1 management. The Maharashtra health department and BMC adopt these centrally, with private hospitals in Mumbai authorized to treat swine flu patients and oseltamivir stocks maintained at both public and private pharmacies.
H1N1 (pandemic influenza A) is susceptible to neuraminidase inhibitors (NAIs) - oseltamivir and zanamivir - but resistant to M2 inhibitors (amantadine, rimantadine), which should NOT be used.
Step 1: Case Classification (ABC Triage System)
All patients presenting with influenza-like illness (ILI) must be triaged into one of three categories:
ILI Definition: Acute respiratory infection (sudden cough + sore throat) with measured fever ≥ 100.4°F (38°C), onset within the last 10 days. Additional symptoms: body aches, headache, fatigue, vomiting/diarrhea, runny/stuffy nose.
Category A - Mild/Uncomplicated
Symptoms: Mild fever + cough/sore throat, with or without body aches, headache, diarrhea, vomiting.
| Parameter | Action |
|---|---|
| Testing | NOT required |
| Antiviral (Oseltamivir) | NOT required |
| Treatment | Symptomatic only - antipyretics (paracetamol), hydration, rest |
| Isolation | Home isolation; avoid contact with high-risk family members |
| Review | Reassess at 24-48 hours |
Note: Do NOT give aspirin to children/adolescents (risk of Reye syndrome).
Category B - Moderate / High-Risk (Two Sub-groups)
B1: Category A symptoms PLUS high-grade fever (≥ 102°F) AND severe sore throat.
B2: Category A symptoms PLUS any of the following high-risk conditions:
- Children aged < 5 years (especially < 2 years)
- Age ≥ 65 years
- Pregnancy or up to 2 weeks post-partum
- Chronic respiratory disease (asthma, COPD)
- Chronic heart, kidney, liver, or neurological disease
- Diabetes mellitus
- Blood disorders (including haemoglobinopathies, sickle cell disease)
- Immunosuppression (HIV/AIDS, long-term steroids ≥ 2 weeks, post-transplant)
- Extreme obesity (BMI ≥ 40 kg/m²)
- Malignancy
- Long-term aspirin therapy in children/adolescents
| Parameter | Action |
|---|---|
| Testing | NOT routinely required |
| Oseltamivir | YES - start immediately along with symptomatic treatment |
| Isolation | Home isolation |
Category C - Complicated / Severe
Symptoms (any one of the following IN ADDITION to A/B symptoms):
| Symptoms | Signs |
|---|---|
| Breathlessness | Tachypnoea |
| Haemoptysis | SpO₂ < 90% |
| Altered mental status / somnolence | Hypotension |
| Seizures | Cyanosis |
| Poor feeding in children | Reduced urine output |
| Decreased urine output | |
| Worsening beyond 72 hours | |
| Worsening of underlying chronic disease |
| Parameter | Action |
|---|---|
| Testing | YES - test for influenza; start empirical oseltamivir WHILE awaiting results |
| Oseltamivir | YES - immediate, do not wait for lab confirmation |
| Hospitalization | MANDATORY - immediate admission |
Step 2: Antiviral Treatment - Oseltamivir (Tamiflu) Dosing
Key principle: Start oseltamivir as early as possible. Starting within 48 hours of symptom onset reduces symptom duration by ~1 day, decreases viral shedding, and may reduce complications. However, treatment benefit extends beyond 48 hours in severe/progressive illness - start at ANY stage if still actively ill.
Adults (including pregnancy):
- Oseltamivir 75 mg twice daily orally for 5 days
- In severe/progressive illness not responding: consider 150 mg twice daily (double dose)
- Pregnancy is NOT a contraindication to oseltamivir
Children (weight-based dosing):
| Age/Weight | Dose |
|---|---|
| > 40 kg | 75 mg twice daily × 5 days |
| 24-40 kg | 60 mg twice daily × 5 days |
| 15-23 kg | 45 mg twice daily × 5 days |
| ≤ 15 kg | 30 mg twice daily × 5 days |
| 3 months - 12 months | 3 mg/kg twice daily × 5 days |
| 1-3 months | 2.5 mg/kg twice daily × 5 days |
| 0-1 month | 2 mg/kg twice daily × 5 days |
Renal impairment:
- Dose adjustment required (oseltamivir is renally excreted)
Step 3: Alternative Antivirals
| Drug | Indication | Dose |
|---|---|---|
| Zanamivir (Relenza) | If oseltamivir unavailable, contraindicated, or oseltamivir-resistant strain | Adults + children ≥ 5 yrs: 2 inhalations (2 × 5 mg) twice daily × 5 days |
| IV Zanamivir / Peramivir / Ribavirin | Persistent severe illness despite oseltamivir (off-label, hospital only) | Specialist decision |
Cautions:
- Ribavirin must NOT be given as monotherapy
- Ribavirin is CONTRAINDICATED in pregnancy
- Zanamivir powder for inhalation must NOT be nebulized (lactose carrier compromises ventilator function)
Step 4: Hospital Management (Category C)
- Oxygen therapy: Early supplemental O₂ to correct hypoxaemia; SpO₂ monitoring at triage and throughout
- Fluid management: Careful IV fluid replacement
- Mechanical ventilation / ICU: For severe ARDS or respiratory failure
- Antibiotics: Cover for bacterial co-infections (secondary pneumonia is common)
- Monitoring: ABG, CBC, CXR, LFT, KFT, blood cultures
Step 5: Chemoprophylaxis
For healthcare workers and close contacts of confirmed/suspected cases:
- Oseltamivir is the drug of choice
- Give until 10 days after the last exposure
- Weight-based dosing (same as treatment, but once daily)
Step 6: Infection Control & Notification
- Mandatory notification: H1N1 is a notifiable disease in Maharashtra - report all confirmed cases to BMC/state health authorities
- Isolation: Home (Cat A & B) or hospital (Cat C) with droplet precautions
- PPE for healthcare workers: Surgical mask minimum; N95 for aerosol-generating procedures
- Avoid aspirin in children and adolescents at all times
Vaccination (Prevention)
- Annual seasonal flu vaccination recommended, especially for high-risk groups
- Current 2026-27 formulation includes H1N1 (A/Victoria/4897/2022-like strain), H3N2, and two B strains
- Priority groups: pregnant women (2nd/3rd trimester), diabetics, hypertensives, elderly, healthcare workers
- Maharashtra state reported a sharp decline in H1N1 cases in 2025 attributed to early treatment protocols, surveillance, and increased vaccination
Quick Reference Summary
| Category | Testing | Oseltamivir | Setting |
|---|---|---|---|
| A (mild) | No | No | Home |
| B1/B2 (high fever or high-risk) | No | Yes | Home |
| C (severe/complicated) | Yes (start treatment immediately) | Yes - immediate | Hospital (mandatory) |
Sources:
- NCDC/MoHFW Seasonal Influenza Guidelines (25 Feb 2019, updated)
- NCDC National Treatment Guidelines - Antimicrobial Use v2.0, Nov 2025
- Park's Textbook of Preventive & Social Medicine, pp. 179-180
- Bradley & Daroff's Neurology in Clinical Practice
This is a shared conversation. Sign in to Orris to start your own chat.